[go: up one dir, main page]

NO960775L - Use of quinoxalins in combination with protease inhibitors as a drug for the treatment of AIDS and / or HIV infections - Google Patents

Use of quinoxalins in combination with protease inhibitors as a drug for the treatment of AIDS and / or HIV infections

Info

Publication number
NO960775L
NO960775L NO960775A NO960775A NO960775L NO 960775 L NO960775 L NO 960775L NO 960775 A NO960775 A NO 960775A NO 960775 A NO960775 A NO 960775A NO 960775 L NO960775 L NO 960775L
Authority
NO
Norway
Prior art keywords
quinoxalins
aids
drug
treatment
combination
Prior art date
Application number
NO960775A
Other languages
Norwegian (no)
Other versions
NO960775D0 (en
Inventor
Arnold Paessens
Martin Blunck
Gunther Riess
Jorg-Peter Kleim
Manfred Rosner
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO960775D0 publication Critical patent/NO960775D0/en
Publication of NO960775L publication Critical patent/NO960775L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det er beskrevet anvendelsen av kinoksaliner l kombinasjon med protease-lnhlbltorer som legemiddel for behandling av AIDS og/eller HIV-lnfeksJoner.The use of quinoxalins in combination with protease inhibitors is described as a drug for the treatment of AIDS and / or HIV infections.

NO960775A 1995-02-27 1996-02-26 Use of quinoxalins in combination with protease inhibitors as a drug for the treatment of AIDS and / or HIV infections NO960775L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19506742A DE19506742A1 (en) 1995-02-27 1995-02-27 Use of quinoxalines in combination with protease inhibitors as medicaments for the treatment of AIDS and / or HIV infections

Publications (2)

Publication Number Publication Date
NO960775D0 NO960775D0 (en) 1996-02-26
NO960775L true NO960775L (en) 1996-08-28

Family

ID=7755115

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960775A NO960775L (en) 1995-02-27 1996-02-26 Use of quinoxalins in combination with protease inhibitors as a drug for the treatment of AIDS and / or HIV infections

Country Status (19)

Country Link
EP (1) EP0728481A3 (en)
JP (1) JPH08245392A (en)
KR (1) KR960030951A (en)
CN (1) CN1141196A (en)
AR (1) AR003923A1 (en)
AU (1) AU710158B2 (en)
BR (1) BR9600809A (en)
CA (1) CA2170222A1 (en)
CZ (1) CZ57896A3 (en)
DE (1) DE19506742A1 (en)
FI (1) FI960850L (en)
HR (1) HRP960070A2 (en)
HU (1) HUP9600455A3 (en)
IL (1) IL117247A (en)
NO (1) NO960775L (en)
NZ (1) NZ286058A (en)
PL (1) PL312908A1 (en)
SK (1) SK25196A3 (en)
ZA (1) ZA961516B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020888A1 (en) * 1996-11-08 1998-05-22 Japan Energy Corporation Aids remedy
DE19703131A1 (en) * 1997-01-29 1998-07-30 Bayer Ag Use of quinoxaline in a combination of three with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of AIDS and / or HIV infections
US6635626B1 (en) 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
WO1999045009A1 (en) * 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
WO2000018384A2 (en) * 1998-09-28 2000-04-06 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
GB9911887D0 (en) * 1999-05-21 1999-07-21 Glaxo Group Ltd Methods and medicaments for post exposure prophylaxis of an hiv infection
DE10013318A1 (en) * 2000-03-17 2001-09-20 Merck Patent Gmbh Quinoxaline derivatives are used as photo-stable UV filters in cosmetic or pharmaceutical sunscreens for the hair or skin
AU2003295605A1 (en) 2002-11-19 2004-06-15 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
CN105229002A (en) * 2012-12-20 2016-01-06 拜耳医药股份有限公司 Dihydropyridopyrazinones that inhibit BET proteins
DE102017005091A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one
DE102017005089A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydroquinoxaline-2 (1H) -one

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0509398B1 (en) * 1991-04-15 2001-09-19 Aventis Pharma Deutschland GmbH Quinoxalines, process for their preparation and their use

Also Published As

Publication number Publication date
ZA961516B (en) 1996-09-03
PL312908A1 (en) 1996-09-02
FI960850A7 (en) 1996-08-28
HUP9600455A2 (en) 1996-12-30
EP0728481A3 (en) 1998-07-08
NO960775D0 (en) 1996-02-26
IL117247A0 (en) 1996-06-18
HUP9600455A3 (en) 1998-04-28
FI960850A0 (en) 1996-02-23
AR003923A1 (en) 1998-09-30
JPH08245392A (en) 1996-09-24
BR9600809A (en) 1997-12-23
CZ57896A3 (en) 1996-09-11
DE19506742A1 (en) 1996-08-29
NZ286058A (en) 1998-09-24
HU9600455D0 (en) 1996-04-29
SK25196A3 (en) 1997-05-07
CN1141196A (en) 1997-01-29
CA2170222A1 (en) 1996-08-28
FI960850L (en) 1996-08-28
IL117247A (en) 2000-10-31
KR960030951A (en) 1996-09-17
EP0728481A2 (en) 1996-08-28
AU710158B2 (en) 1999-09-16
HRP960070A2 (en) 1997-10-31
AU4561596A (en) 1996-09-05

Similar Documents

Publication Publication Date Title
FI981591A7 (en) HIV protease inhibitors useful in the treatment of AIDS
FI955315L (en) HIV protease inhibitors useful in the treatment of AIDS
RU95106823A (en) Succinoylaminohydroxyethylaminosulfonamides, pharmaceutical composition, method of inhibition of retroviral protease, method of treatment of retroviral infection, method of aids treatment
NO960775L (en) Use of quinoxalins in combination with protease inhibitors as a drug for the treatment of AIDS and / or HIV infections
BG98902A (en) IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKIN INHIBITORS
FI954580A7 (en) HIV protease inhibitors in pharmaceutical combinations for use in the treatment of AIDS
FI893962A7 (en) HIV protease inhibitors, which are useful in the treatment of AIDS
EP1210941A3 (en) Pharmaceutical compositions containing ritonavir (ABT-538) in combination with indinavir (MK-639) and their use for treating AIDS
MD1507F2 (en) Inhibitors, pharmaceutical composition on base thereof and process for HIV protease inhibition
DK0951473T3 (en) Cyclosporin derivative, preparation thereof and pharmaceutical preparations containing this
DK0703786T3 (en) Use of nona- and decapeptides for the manufacture of a medicament for the treatment of AIDS
FI923158A7 (en) HIV protease inhibitors, which are useful in the treatment of AIDS
DK1332757T3 (en) Compressed tablet formulation containing efavirenz
FI935777L (en) HIV protease inhibitors useful in the treatment of AIDS
NO993670L (en) Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS
NO934721D0 (en) HIV protease inhibitors useful for the treatment of AIDS
NO934720L (en) New HIV protease inhibitors
TR200401363T4 (en) Treatment of DNA viral infections
NO932130D0 (en) INHIBITORS OF HIV PROTEASE USED FOR TREATMENT OF AIDS
ES2105605T3 (en) TAQUIQUININE ANTAGONISTS, THEIR PREPARATION AND USE IN PHARMACEUTICAL FORMULATIONS.
DE69628819D1 (en) COMBINATION THERAPY OF HIV INFECTION USING THE HIV PROTEASE INHIBITOR INDINAVIR AND THE INHIBITOR OF REVERSE TRANSCRIPTASE 3 TC WITH AZT.
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
ES2191206T3 (en) NEW USE OF CREATINE.
FI952018L (en) Use of BHAPs in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection
AU1873101A (en) Synergistic treatment of dna viral infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application